1. "Thoracic Oncology"
  2. "Nursing"
Formats
  1. Journal Article (93)
  2. Meeting Abstract (64)
  3. Conference Paper (4)
  4. Miscellaneous (1)
Groups
  1. Department of Medicine (162)
  2. Nursing (162)
  3. Solid Tumor Oncology Division (162)
  4. Thoracic Oncology (162)
  5. Advanced Practice Providers (49)
  6. Center for Pancreatic Cancer Research (45)

More Groups

People
  1. Mark Kris (111)
  2. Leslie Tyson (53)
  3. Vincent Miller (35)
  4. Lee Krug (33)
  5. Barbara Pizzo (29)
  6. Christopher Azzoli (23)

More People

Years
  1. 2024 (2)
  2. 2023 (7)
  3. 2022 (12)
  4. 2021 (6)
  5. 2020 (9)
  6. 2019 (8)

More Years

Publications
  1. Journal of Clinical Oncology (52)
  2. Cancer (16)
  3. Clinical Cancer Research (12)
  4. Journal of Thoracic Oncology (12)
  5. Lung Cancer (6)
  6. Annals of Oncology (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (58)
  2. American Association for Cancer Research (23)
  3. Elsevier Inc. (16)
  4. Wiley Blackwell (16)
  5. Oxford University Press (12)
  6. Elsevier Ireland Ltd. (6)

More Publishers

Results (162)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers
    Journal Article

    Rustgi, N.; Maria, A.; Toumbacaris, N.; Zhao, H.; Kargus, K.; Bryant, M.; Waksmundzki, A.; Aricescu, I.; Lefkowitz, R. A.; Li, B. T.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Quantifying the expanding landscape of clinical actionability for patients with cancer
    Journal Article

    Suehnholz, S. P.; Nissan, M. H.; Zhang, H.; Kundra, R.; Nandakumar, S.; Lu, C.; Carrero, S.; Dhaneshwar, A.; Fernandez, N.; Xu, B. W.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Phase I study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations: Pilot analysis of circulating tumor DNA for patient eligibility confirmation and post-treatment response
    Meeting Abstract

    Imber, B.; Ravichandran, V.; Rao, P.; Casanova, H.; Friend, J.; Simpson, J.; Pike, L.; Zinovoy, M.; Mitchell, R.; Chacko, C.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib in patients with MET-altered lung cancers
    Meeting Abstract

    Harada, G.; Santini, F. C.; Repetti, R. W.; Chang, J.; Yang, S. R.; Lin, Y. T.; Moses, K. A.; Falcon, C.; Wilhelm, C. J.; Goldstein, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabis
    Meeting Abstract

    Salz, T.; Chimonas, S.; Jinna, S.; Brens, J.; Kriplani, A.; Salner, A. L.; Rabinowits, G.; Currier, M.; Daly, R. M.; Korenstein, D.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Quantifying the growth of clinical actionability in precision oncology using OncoKB
    Meeting Abstract

    Suehnholz, S. P.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Zhang, H.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Molecular characterization of acquired resistance to KRAS(G12C)–EGFR inhibition in colorectal cancer
    Journal Article

    Yaeger, R.; Mezzadra, R.; Sinopoli, J.; Bian, Y.; Marasco, M.; Kaplun, E.; Gao, H.; Zhao, H. Y.; Paula, A. D. C.; Zhu, Y.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation
    Meeting Abstract

    Murciano-Goroff, Y. R.; Kannan, S.; Chang, J. C.; Benayed, R.; Blokhin, I.; Rekhtman, N.; Sisk, A. E.; Gibson, J.; Judka, L.; Kaplanis, L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save